Q3 2025 ALX Oncology Holdings Inc Earnings Call Transcript
Key Points
- ALX Oncology Holdings Inc (ALXO) presented promising data from the ASPEN-06 trial, showing CD47 expression as a key predictive biomarker for evorpacept in HER2-positive gastric cancer patients.
- The company reported significant advances in both evorpacept and ALX2004 clinical programs, with evorpacept showing strong efficacy in patients with high CD47 expression.
- ALX Oncology Holdings Inc (ALXO) has a robust cash balance of $67 million, expected to provide runway into the first quarter of 2027.
- The company is on track to dose the first patient in its Phase II breast cancer trial this quarter, targeting CD47 and HER2 biomarker-driven strategies.
- ALX2004, a novel EGFR-targeted ADC, is progressing well in clinical trials, with patients currently being enrolled in the second dose cohort.
- The conventional approach to CD47 targeting has caused significant toxicities in some patients, highlighting potential safety concerns.
- The company faces challenges in developing a companion diagnostic for CD47 expression, which is crucial for patient selection in trials.
- There is no standard of care for patients who have been treated with trastuzumab deruxtecan, creating uncertainty in treatment pathways.
- The efficacy of evorpacept in breast cancer trials is still being evaluated, with no clear data yet on CD47 high versus low populations.
- The market opportunity for evorpacept is contingent on successful targeting of CD47 high and HER2-positive patients, which represents a subset of the overall patient population.
Greetings and welcome to the ALX Oncology third-quarter 2025 financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Jason Lettmann. You may begin.
Thanks, everyone, and welcome to our Q3 2025 results. I appreciate everybody spending some time with us this morning, and I'm looking forward to this update. On slide 2 here before we start our presentation of housekeeping here are our forward-looking statements for your review. So on the next slide, slide 3 here, here is the agenda and our plan for today.
We're going to be providing an update on our key accomplishments in the third quarter of 2025. Most notably, we are very excited to share with you the data set that will be presented at SITC this weekend from a preplanned analysis of our ASPEN-06 trial that showed CD47 expression as a key predictive biomarker for increasing durable clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
